Investors & Media
<< Back
Jun 04, 2018

TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer

NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the appointment of Adam Waldman as Chief Commercial Officer.  Mr. Waldman brings extensive experience commercializing products in oncology and hematology, most recently as the Head of US Hematology-Oncology Marketing at Celgene Corporation, and has an extensive track record of successfully launching multiple brands. 

Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased to welcome Adam to the TG Therapeutics team. He brings extensive experience to the company and as we move towards commercialization he will be an invaluable member of the team.  I look forward to working with him and driving towards our goal of bringing novel combination treatment options to patients with B-cell malignancies.”

Adam Waldman stated, “I am thrilled to be joining TG Therapeutics with the opportunity to build a world class commercial team and to launch multiple new products over the next few years. TG has a unique patient centered approach and several promising late stage assets addressing high unmet needs.”

Mr. Waldman joins TG Therapeutics with more than 20 years of experience in the biotechnology and life science industries.  Most recently, Mr. Waldman served as the Head of US Hematology-Oncology Marketing at Celgene Corporation where he spent the past 13 years in various roles of increasing responsibility in sales, marketing and new product strategy. Adam brings extensive experience and a proven track record of success building high performing teams and launching transformational products in both hematology and oncology. Prior to Celgene, Mr. Waldman was at Schering Plough where he was responsible for coordinating the global marketing strategy for multiple oncology products.  Mr. Waldman holds an MBA in Finance from the University of Rochester, Simon Business School as well as a B.S. in Biological Science from Rutgers College.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future.  TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release or in the abstracts mentioned in this press release may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete preclinical and clinical trials; the risk that early clinical trial results (both safety and efficacy), will not be reproduced in future studies; the risk that the combination of ublituximab (TG-1101) and umbralisib (TGR-1202), referred to as U2, and being studied in the UNITY clinical trials and other studies, will not prove to be safe and efficacious for any indication; the risk that the final data from either GENUINE or UNITY-CLL will not support a regulatory filing or approval or that the company will choose not to file a BLA/NDA or seek accelerated approval based on those studies; the risk that our products under development do not achieve regulatory approval; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission.  Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

CONTACT:  
   
  Jenna Bosco
  SVP, Corporate Communications 
  TG Therapeutics, Inc.
  Telephone: 212.554.4351
  Email: ir@tgtxinc.com

 

Primary Logo

Source: TG Therapeutics, Inc.